There are two major pathways for T-cell regeneration after allogeneic bone marrow transplantation; thymus-dependent T-cell differentiation of T-cell progenitors, and peripheral expansion of mature T cells in the graft. In order to learn to what extent the peripheral expansion of donor-derived mature T lymphocytes contributes to reconstitution of the TCRab+ T-cell repertoire after allogeneic bone marrow transplantation for adult myeloid leukemias, we pursued the fate of donorderived T-cell clones using the amino-acid sequences of the complementarity-determining region 3 (CDR3) of the TCR-b chain as a clonal marker. Clonal expansion of TCRab+ T lymphocytes with specific TCRBV subfamilies was identified in donor blood. Identical T-cell clones were not found in blood from recipients before transplantation. The donor-derived T-cell clones were identified in the circulating blood from recipients a few months after allogeneic bone marrow transplantation, and they remained in the blood for 18 months after transplant in two recipients, and for 56 months in one. These results suggest that the peripheral expansion of mature T lymphocytes in the graft makes a significant contribution to post-transplant T-cell regeneration during the early period of transplantation in humans, and that mature T cells can survive in recipients for several years. Further investigation will be required to explore which antigens drive the expansion of T-cell clones in donors and recipients, and the mechanisms of maintaining homeostatic balance between the thymus-dependent pathway and the peripheral expansion of mature T cells in post-transplant T-cell regeneration.
Introduction
Transfer and reconstitution of T-cell immunity is critical for successful allogeneic hematopoietic stem cell transplantation (HSCT) for treating not only congenital immunodeficiency syndrome but also hematological malignancies. T-cell regeneration and reconstitution of the T-cell repertoire are potentially achieved by the thymus-dependent and thymus-independent differentiation of T-cell progenitors, and the peripheral expansion of mature T cells in the graft. 1 In humans, thymic T-cell regenerative capacity declines relatively early in life, suggesting that the thymus-independent pathway may play a crucial role in T-cell regeneration after hematopoietic stem cell transplants in adults. 2 However, the mechanisms of T-cell regeneration after human allogeneic HSCT remain elusive.
We showed that the skewed T-cell receptor a-and b-chain variable region (TCRAV and TCRBV) repertoires that are present soon after human allogeneic HSCT 3 last for several years. We also showed that the ab+T-cell repertoire recovers faster in recipients of blood hematopoietic stem cells mobilized by G-CSF than in those who receive bone marrow from allogeneic donors. 4 Moreover, we found that a skew of the T-cell repertoire can be caused by the clonal expansion of TCRab+CD8+CD28À T cells, 5 and that consensus motifs of amino acids are observed in the complementarity-determining region 3 (CDR3) of clonally expanded T cells among distinct recipients. 6 Animal studies have shown that injecting athymic mice with a limited number of mature T lymphocytes skews the T-cell repertoire, the regeneration of which is affected by the host antigenic milieu. 7 Therefore, the above features of T-cell repertoire reconstitution suggest that the peripheral expansion of donor-derived mature T lymphocytes plays a certain role in T-cell regeneration after human HSCT. We reported that the TCRgd+ T lymphocyte repertoire during the early period of transplantation is reconstituted via the mechanism of peripheral expansion of mature T cells in grafts. 8 The present study examines whether this is also true with respect to regeneration of the TCRab+ T-cell repertoire after transplantation with human allogeneic hematopoietic stem cells and how long donor-derived mature T cells are detectable in the recipient.
Materials and methods

Patients
Written informed consent was obtained from all patients and donors before blood samples were collected and the ethical committee of our institution approved the experimental protocol. The characteristics of the three adult patients with myeloid leukemias included are listed in Table 1 . All the patients were conditioned with myeloablative chemoradiotherapy, consisting of fractionated total body irradiation (12 Gy in six fractions) and cyclophosphamide (60 mg/kg/day for 2 days), followed by an infusion of unmanipulated allogeneic marrow grafts from HLAmatched donors. All patients received prophylactic cyclosporin A and short-term methotrexate against acute graft-versus-host disease (GVHD). 9 Engraftment was confirmed by the recovery of hematopoiesis and the presence of donor-derived sex chromosomes or mismatched antigens on red cells. Clinical grading of acute GVHD was determined according to the criteria reported by Glucksberg et al. 10 Patients were monitored for cytomegalovirus (CMV) infection by weekly CMV antigenemia assays 11 from the day the granulocyte count reached 500/ml until day 100 after transplantation. Patients who were positive for the CMV antigenemia assay received prophylactic ganciclovir (5 mg/kg/ day, 3 days per week) when the granulocyte count reached over 1000/ml.
PCR amplification and CDR3 size distribution analysis of the TCR-b-chain
Analysis of CDR3 sizes of any given TCR-b chains allows the estimation of clonal expansion over the polyclonal background. 13 We used this technique to detect the clonal expansion of TCRab+ T lymphocytes. We isolated peripheral blood mononuclear cells (PBMCs) from 10 ml of heparinized blood and extracted total RNA using an RNeasy Total RNA Kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was synthesized using a First-Strand cDNA Synthesis Kit with an oligo-dT primer (Amersham Pharmacia Biotech, Uppsala, Sweden). 14, 15 Aliquots of the cDNA were amplified using Vband Cb-specific primers. The sequences of the Vb and Cb primers are shown in Table 2 . 4, 16 Sequences were amplified by PCR in a 20 ml reaction mixture containing 0.2 mM of each primer and 0.5 U of Taq polymerase (TaKaRa, Osaka, Japan) in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , and 0.2 mM of each dNTP. The amplification conditions consisted of 40 cycles of denaturation at 941C for 1 min, annealing at 551C for 1 min, and extension at 721C for 1.5 min followed by a single extension at 721C for 15 min.
Aliquots (4 ml) of unlabeled Vb-Cb PCR products were subjected to one cycle of elongation (runoff reaction) with a FAM-labeled nested Cb primer (FAM-CB3) under the following conditions: denaturation at 941C for 2 min, annealing at 551C for 1 min, and extension at 721C for 15 min in the buffer described above. Labeled PCR products were mixed with a size marker (GeneScan-500 TAMRA, Applied Biosystems, Warrington, UK), and resolved on 5% polyacrylamide sequencing gels. Size and fluorescence intensity of the products were determined using an automated DNA sequencer (ABI 377, Perkin-Elmer Applied Biosystems, Foster, CA, USA). Data were analyzed using GeneScan software (Perkin-Elmer Applied Biosystems).
Sequencing of CDR3 region in the TCR-b chain
The TCRBV-CDR3 size distribution of donor lymphocytes was compared with that of recipient lymphocytes to identify skewed TCRBV subfamilies with clonal peaks that were the same size between donor and recipient. We cloned the PCR products of 
Table 2
Nucleotide sequences of the TCRBV and TCRBC primers
GAACTGGACTTGACAGCGGAACT TCRBC FAM-CB3 FAM-ACTGTGCACCTCCTTCCCATTCA TCRBC a TCRBV gene segments are described according to nomenclature reported by Concannon et al. 48 Peripheral expansion of T cells after allo-BMT H Saitoh et al the selected TCR-b chain into the PCR2.1 TA cloning vector (Invitrogen, Carlsbad, CA, USA) and sequenced them using BigDye Terminator Cycle Sequencing Kits (Perkin-Elmer Applied Biosystems) and an Applied Biosystems 377A automated DNA sequencer.
Repertoire analysis of TCRBV TCRBV repertoire was analyzed using an adaptor-ligation PCRbased microplate hybridization assay, as described. 17, 18 Briefly, total RNA was extracted from PBMCs, and converted to doublestrand cDNA using a SuperScript cDNA synthesis kit (BRL, Bethesda, MD, USA). The P10EA/P20EA adaptors were ligated to the 5 0 end of cDNA, and PCR was performed using a biotinylated TCRBC (TCR-b chain constant region)-specific primer and a P20EA primer. 19 Biotinylated PCR products were hybridized with an immobilized TCRBV-specific primer in 96-well microtiter plates. Subsequently, alkaline phosphataseconjugated streptavidin was added to each well and a colorimetric assay was performed. After color development, absorbance was determined at 405 nm and data were directly transferred to a computer for calculation. The optical density (OD) of the wells containing immobilized TCRBV-specific probes was standardized according to the hybridization efficiency of each of them. The corrected OD values were used to calculate the relative frequency of TCRBV usage. The formula is as follows: relative frequency (%) ¼ corrected OD with a TCRBV-specific probe Â 100/ sum of corrected OD values with TCRBV-specific probes.
Results
Identification of skewed TCRBV subfamilies used by peripheral blood T lymphocytes in a donor and a post-transplant recipient
To determine identical T-cell clones that expanded in donors and in post-transplant recipients, we firstly examined the CDR3 size distribution of 36 TCRBV subfamilies used by circulating blood T lymphocytes. Figure 1 shows representative data. The donor for patient UPN01 had several skewed TCRBV subfamilies, such as VB6-4, VB11-1, VB15-1, VB16-1, and VB24-1 ( Figure 1a ). These were also skewed in the recipient on day 60 after transplantation, when they had become even more oligoclonal (Figure 1b) . A clonal peak of 354 base pairs (bp) was identified in TCRBV16 in both the donor and the recipient, suggesting that the peaks included identical T-cell clones. Two more patients were similarly analyzed and we found clonal expansion of some TCRBV subfamilies of the same size in both donor and recipients (data not shown).
Longitudinal analysis of CDR3 size distribution revealed that the 354 bp clone repeatedly predominated on days 56, 187, and 551 in patient UPN01 (Figure 2a ). However, a distinct clonal peak was detected on day 1814. A 306 bp peak detected in the donor appeared in the recipient UPN02 after transplantation, and another clonal peak predominated on day 1479 (Figure 2b ).
Identification of donor-derived T-cell clones in recipients after allogeneic bone marrow transplantation
To confirm and pursue the fate of donor-derived mature T cells, we subcloned and sequenced the CDR3 region of the clonally expanded T cells with skewed TCRBV subfamilies in three recipients. We confirmed clonal expansion of TCRBV16S1 with a -DRGRS-junctional sequence in the peripheral blood of the donor for patient UPN01 by colony frequency (12 of 17 clones) ( Table 3 ). This clone was not detectable in the recipient before transplantation. On day 56 after transplantation, we identified a T-cell clone with a -DRGRS-junctional sequence and with limited diversity in the recipient's blood. This donor-derived Tcell clone was also expanded by days 187 and 551 with more diversified repertoires. On day 1814, this clone was not dominant, but other T-cell clones with -VGQG-and -EGTGSjunctional sequences had expanded. These T-cell clones were not identified in blood from either the donor or the recipient prior to transplantation.
We performed the same analysis in another two patients. We confirmed the clonal expansion of TCRBV21S1 with a -GGE-CDR3 sequence in the donors for patient UPN02 (Table 4) . Undetectable in the recipient before transplant, we detected this T-cell clone on day 57 after transplant. The identical subfamily had diverse repertoires by days 291 and 550. On day 1479, a distinct clone that was not found in the donor or in the pretransplant recipient predominated with an obviously skewed repertoire. We confirmed the clonal expansion of TCRBV6S2 with -STGY-, -GAVF-and -AAGA in the donor for UPN03 (Table 5 ). Before transplant, this clone was not identified in the blood from recipient. Rather, a distinct clone expanded in the recipient. Donor-derived T-cell clones with -STGY-and -AAGAjunctional sequences appeared on day 60, and both clones remained by day 1683, with limited diversity.
Presence of multiple donor-derived mature T lymphocyte clones in a long-term survivor after allogeneic transplantation
We extended our observation to see if the persistence of donorderived mature T lymphocyte clones in post-transplant recipients is also observed in other TCRBV subfamilies. We performed CDR3 sequence analysis for several TCRBV subfamilies that showed the skewing in both the donor for UPN01 patient and the post-transplant recipient such as VB5-1, VB5-4, VB15-1, and VB24-1 ( Figure 1 and Table 6 ). As shown in Table 6 , multiple T-cell clones were identified in both the samples, suggesting that a considerable part of the donor-derived T-cell clones can persist in the recipient.
Chronological changes of TCRBV repertoire associated with CMV disease
The results described above have confirmed the previous finding that the detection of clonal T-cell expansions is the common feature in healthy individuals. 20, 21 It has recently been demonstrated by using HLA-peptide tetramers that CMV epitopespecific CD8+ T cells are clonally expanded in healthy old age CMV-seropositive individuals, although these clones are also found in young CMV-seropositive donors. 22 All three donors included in the present study were seropositive for CMV. These results prompted us to examine the chronological profiles of TCRBV repertoire in recipients who developed CMV disease after transplantation. Among three patients in the present study, the UPN02 patient developed CMV-associated interstitial pneumonia. As shown in Table 4 , TCRBV21S1+ T cells were clonally expanded in donor blood for the UPN02 patient. An adaptor-ligation PCR-based microplate hybridization analysis of
Peripheral expansion of T cells after allo-BMT
H Saitoh et al Figure 1 CDR3 size distribution of TCR-b chains in a donor (a; UPN01 patient) and recipient (b) pair. VB16-1 is skewed and a clone of 354 bp predominates in both the donor and recipient. The recipient was examined 2 months after transplantation. 
H Saitoh et al TCRBV repertoire in the UPN02 patient revealed that the usage of TCRBV21 subfamily was within normal range during the early period after transplantation, but it was increased after the onset of CMV-IP, lasting for several months (Figure 3 ).
Discussion
The generation and maintenance of a diverse T-cell repertoire are essential for immune competence. During T-cell ontogeny before birth, repertoire diversity is generated within the thymus through random TCR gene rearrangement, 23 followed by positive selection of the cells bearing TCRs with specificities for the antigen in the context of host MHC, and negative selection of potentially autoreactive T cells. [24] [25] [26] [27] However, whether the thymus-dependent pathway is the principal mechanism of T-cell regeneration after human allogeneic HSCT, especially in adult patients, remains obscure. Table 3 Deduced amino-acid sequences of CDR3 region of TCRBV16S1 in blood T lymphocytes from donor and recipient (UPN01 patient) before and after transplantation T-cell clones appearing more than twice in each sample are presented except for the sample from the pretransplant recipient. See footnote of Table 3 .
Peripheral expansion of T cells after allo-BMT H Saitoh et al
The production of post-transplant naive T-cells by the thymus and peripheral expansion of T cells can be estimated by analyzing T-cell receptor excision circles (TRECs) and by the expression of CD45 isoforms and CD27 antigens, respectively. [28] [29] [30] Soon after transplantation, the numbers of circulating T cells are thought to be low, with predominating mature CD45RO+ T cells, and that the TREC contents in naive T cells become normalized several months after transplantation. 29, 30 However, these analyses cannot determine whether given T-cell clones are derived from mature T cells in the graft or whether they are recent thymic emigrants. Thus, we used CDR3 sequences as clonal marker of T cells.
Evidence suggests that donor-derived mature T lymphocytes constitute a crucial component of successful allogeneic HSCT in the treatment of hematological malignancies. 31, 32 Remission has been achieved by donor lymphocyte infusion (DLI) for relapsed chronic myeloid leukemia [33] [34] [35] and nonmyeloablative stem transplantation has been successful against refractory indolent lymphoma and myeloma. 36, 37 Important issues are the length of time that donor-derived mature T cells can remain in recipients, and the duration of immunosurveillance by leukemia-specific T lymphocytes that is required to result in a cure. Clinical studies have demonstrated that leukemia relapse is infrequent 2 or 3 Table 5 Deduced amino-acid sequences of CDR3 region of TCRBV6S2 in T lymphocytes from donor and recipient (UPN03 patient) blood before and after transplantation T-cell clones that were detected in both the donor and post-transplant recipient (UPN01) are shown with their colony frequencies. The TCRBV5S6 segment was amplified by mispriming. The T cells using TCRBV21 in donor blood accounted for 2.8% of total TCRab+ T cells. 32 Studies of minimal residual disease in chronic myelogenous leukemia have revealed that bcr-abl transcripts are often detected within the first year of allogeneic transplant, and that most patients become PCR negative within 2 years after transplant. 38 Moreover, Claret et al 39 have demonstrated that the clonal expansions of allogeneic T cells are mediators of antileukemic activity by DLI. These results suggest that leukemia eradication by allogeneic mature T lymphocytes and a resulting cure might require a few years. The present study demonstrated that donor-derived mature TCRab+ T lymphocytes could survive in recipients for several years, and that persistence of donor-derived T-cell clones was not limited to a few clones. These results suggest that donor-derived mature T lymphocytes make a significant contribution to the reconstitution of T-cell repertoires at least during the first few years of transplants, and that those repertoires might contain T cells responsible for graftversus-leukemia effect.
Peripheral expansion of T cells after allo-BMT
Mackall et al 7 have reported that antigen-driven expansion of mature T cells is the primary mechanism by which T-cell populations are regenerated in vivo in the absence of a functional thymus. Therefore, it is also likely in humans that persistent clonal expansion in recipients of allogeneic stem cell grafts might have been driven by endogenous antigens in the recipient. However, direct evidence of the antigens that are responsible for maintaining the clonal expansion of donorderived mature TCRab+ T lymphocytes for many years after transplant remains elusive. We reported that recipients of allogeneic bone marrow grafts have clonally expanded TCRab+ T lymphocytes soon after transplantation, leading to a skew of TCR repertoires, 3, 6 and that the usage of TCRAV and TCRBV by the clonally expanded T lymphocytes and their CDR3 sequences differ between the GVHD and blood. 40 Thus, the clonal expansion of T cells in blood does not necessarily mean allogeneic T-cell responses.
As described earlier, there is accumulating evidence that clonal T-cell expansions are detected in healthy individuals. [20] [21] [22] Moreover, it has become clear that persistent CMV infection makes a contribution to shaping the T-cell repertoire toward greater clonality in CMV-seropositive healthy individuals. 22, 41 Since bone marrow donors for allogeneic HSCT in the present study had never received blood transfusion or organ transplantation, clonal T-cell expansions in donor should not have been driven by allogeneic antigens. A transient increase of the donorderived T cells carrying the TCRBV21 subfamily in the UPN02 patient in association with post-transplant CMV disease suggests that antigen specificity of the donor-derived T-cell clones expanded in blood of HSCT recipients might include CMV. Further experiments are required to determine the antigen specificities of the T-cell clones expanded in both donors and recipients using other strategies such as MHC/peptide tetramers in a prospective study. [43] [44] [45] [46] [47] In conclusion, we present direct evidence that the peripheral expansion of donor-derived mature T cells contributes to the reconstitution of TCRab+ T cells soon after human allogeneic HSCT, and that some T-cell clones can survive for several years. Our results do not exclude the role for thymus-dependent pathway in T-cell reconstitution after human allogeneic HSCT. The homeostatic balance between the thymic pathway and the peripheral expansion needs be explored.
